CompoAtlas

Rutine 750 diosmine hespéridine

Food supplement declared in France, decision dated 24 December 2024

Rutine 750 diosmine hespéridine (Kersiens) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: rutine 750 mg per day, diosmine 200 mg per day, hespéridine 50 mg per day, Vitamin C. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Kersiens
Food business operator placing the product on the market
Pharm nature micronutrition
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
3 gélules par jour
Directions for use
2 gélules le matin et 1 le soir, de préférence au cours du repas
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Pregnant women, Taking blood pressure medication
Objectives stated by the manufacturer (these are not authorised claims)
Blood and lymphatic circulation

Declaration 3056, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Substances

NamePer day
rutine750 mg
diosmine200 mg
hespéridine50 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
L-ascorbic acidVitamin Cno limit (insufficient data)180 mg

Additives

E141

Other ingredients

Gélatine marine, maltodextrine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Réservé à l’adulte. Déconseillé aux femmes enceintes ou allaitantes ainsi qu’aux personnes sous traitement anti-hypertenseur. À consommer dans le cadre d’un mode de vie sain et d’un régime alimentaire varié et équilibré. Ne pas dépasser la dose journalière indiquée. Tenir hors de portée des jeunes enfants.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • rutine
    Read the warning, when it applies and the studies cited

    RUTIN

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (PDR 2008).

    Sources cited by Health Canada (1)
    • PDR 2008: Hendler SS, Rorvik D. PDR for Nutritional Supplements. 2nd edition. Montvale (NJ): Thomson Healthcare; 2008.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : Kersiens

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Rutine 750 diosmine hespéridine (Kersiens): composition and regulation”, https://compoatlas.com/en/supplements/products/3056-rutine-750-diosmine-hesperidine, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line